XTL Biopharmaceuticals shares rise 26.71% premarket after acquiring 85% of NeuroNOS, entering massive autism market with Nobel Prize-winning leadership.

XTL Biopharmaceuticals surged 26.71% in premarket trading following the announcement of acquiring 85% of NeuroNOS, a subsidiary of Beyond Air, to enter the autism market. The deal leverages Nobel Prize-winning scientific leadership, positioning the company to capitalize on a high-growth therapeutic segment. This strategic acquisition underscores XTL’s expansion into neurodevelopmental treatments, likely boosting investor confidence in its long-term prospects. The upcoming extraordinary general meeting on February 17, 2026, to approve corporate actions is not directly linked to the premarket rally.